Repligen Completes Expansion of Manufacturing Facility
Repligen completes expansion of its manufacturing facilities at its Massachusetts headquarters.
Repligen has completed a 9,000-ft2 expansion of its manufacturing facilities at its Waltham, Massachusetts’s headquarters. The production suite more than doubles capacity for Repligen’s OPUS line of prepacked chromatography columns, with cleanrooms built to ISO 7 specifications providing an appropriately controlled environment for GMP production.
The facility expansion also triples warehouse space and includes purification and fermentation laboratories for optimization of existing manufacturing processes, new product development, and applications support. An additional 17,000 ft2 of space is reserved for future expansion of the same facility.
Source: Repligen
FDA Reopens Comment Period on HCP Immunogenicity Risk of Follow-on Recombinant Peptides
January 2nd 2025FDA is reopening the comment period for the Federal Register Notice, “Evaluating the Immunogenicity Risk of Host Cell Proteins in Follow-on Recombinant Peptide Products: Establishment of a Public Docket: Request for Information and Comments”, until March 3, 2025.
